Literature DB >> 9869836

Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products.

S Itescu1, J H Artrip, P A Kwiatkowski, S F Wang, O P Minanov, A S Morgenthau, R E Michler.   

Abstract

We have previously described a form of xenograft rejection, mediated by natural killer (NK) cells, occurring in pig-to-primate organ transplants beyond the period of antibody-mediated hyperacute rejection. In this study, two distinct NK activation pathways were identified as mechanisms of pig aortic endotheliual cell (PAEC) lysis by human NK cells. Using an antibody-dependent cellular cytotoxicity (ADCC) assay, a progressive increase in human NK lysis of PAEC was observed following incubation with human IgG at increasing serum titer. In the absence of IgG, a second mechanism of PAEC lysis by human NK cells was observed following activation with IL-2. IL-2 activation of human NK cells increased lysis of PAEC by over 3-fold compared with ADCC. These results indicate that IL-2 activation of human NK cells induces significantly higher levels of lytic activity than does conventional ADCC involving IgG and FcRIII. We next investigated the role of MHC class I molecules in the regulation of NK lysis following IL-2 activation. PAEC expression of SLA class I molecules was increased by up to 75% by treatment with human TNFa. Following treatment with TNFa at 1 u/ml, IL-2 activated human NK lysis of PAEC was inhibited at every effector:target (E:T) ratio tested. Maximal effect occurred at an E:T ratio of 10:1, with TNFa inhibiting specific lysis by 59% (p < 0.01). Incubation with an anti-SLA class I Mab, but not IgG isotype control, abrogated the protective effects of TNFa on NK lysis of PAEC, suggesting direct inhibitory effects of SLA class I molecules on human NK function. To investigate whether human MHC class I molecules might have similar effects on human NK lysis of PAEC, further experiments were performed using a soluble peptide derived from the alpha-helical region of HLA-B7. Incubation with the HLA-B7 derived peptide significantly reduced the IL-2 activated NK lytic activity against PAEC in a dose-dependent fashion. Maximal effect occurred at a concentration of 10 mg/ml, where an 8-fold reduction in IL-2 augmented NK lysis was observed (p < 0.01). These results suggest that IL-2 activated human NK lysis of porcine xenografts may be inhibited by strategies which increase PAEC expression of SLA class I molecules, introduce HLA class I genes into PAEC, or use soluble HLA class I peptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9869836

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  5 in total

1.  Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse Model.

Authors:  H W Li; P Vishwasrao; M A Hölzl; S Chen; G Choi; G Zhao; M Sykes
Journal:  Am J Transplant       Date:  2016-08-10       Impact factor: 8.086

Review 2.  IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.

Authors:  Megan Sykes
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

3.  Human CD200 suppresses macrophage-mediated xenogeneic cytotoxicity and phagocytosis.

Authors:  Rieko Sakai; Akira Maeda; Thuy-Vy Choi; Pei-Chi Lo; Patmika Jiaravuthisan; Afifah Mod Shabri; Han-Tang Wang; Rei Matsuura; Tasuku Kodama; Hiroshi Eguchi; Hiroomi Okuyama; Shuji Miyagawa
Journal:  Surg Today       Date:  2017-06-01       Impact factor: 2.549

Review 4.  Biology and clinical impact of human natural killer cells.

Authors:  Sherif S Farag; Jeffrey B VanDeusen; Todd A Fehniger; Michael A Caligiuri
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 5.  The Role of NK Cells in Pig-to-Human Xenotransplantation.

Authors:  Gisella Puga Yung; Mårten K J Schneider; Jörg D Seebach
Journal:  J Immunol Res       Date:  2017-12-19       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.